Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fendrix and HBVAXPRO 40 in Chronic Liver Disease
NCT03459521Completed
- Sponsor
- Hospital Universitari Parc Taulí
- Start
- Sep 2017
- Primary completion
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Hepatitis B vaccine and Recombivax HB in hepatitis B virus infection, sponsored by Hospital Universitari Parc Taulí. Primary endpoint: Proportion of individuals seroconverting with Hepatitis B surface antibody titres of > 10 and > 100 UI/ml at 8 months. Started Sep 2017; status: completed.
02
Drugs
Hepatitis B vaccineRecombivax HB
03
Conditions
hepatitis B virus infection
Beyond the preview
Go deeper on NCT03459521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459521.